Literature DB >> 12729717

Etiology of cecal and hepatic lesions in mice after administration of gas-carrier contrast agents used in ultrasound imaging.

H Rasmussen1, H A A M Dirven, D Grant, H Johnsen, T Midtvedt.   

Abstract

The aim of the study was to investigate the etiology of cecal and hepatic lesions in mice and rats after intravenous administration of gas-carrier contrast agents (GCAs). A modified fluorescein flowmetry technique and 24 h necropsy were used in mice (conventional and germ free), rats, and guinea pigs after GCA administration. Different diets and oral nonabsorbable antibiotics were used. Nonfluorescence, edema, congestion, hemorrhage, and mucosal erosion in cecum and colon and nonfluorescent areas in the liver were observed from 16 min after GCA administration in conventional mice on standard diet. Numerous gas bubbles (>50 microm) were observed in the vasculature around the nonfluorescent areas of cecum and colon and in mesenteric vessels draining to the portal vein. Acute inflammation, edema, hemorrhage, and ulceration of the cecum and colon and liver necrosis were seen 24 h after GCA administration in conventional mice on standard diet. When mice were maintained on either a diet with glucose as the only carbohydrate source or on a standard diet supplemented with antibiotics, uniform fluorescence and no organ lesions were observed after GCA administration. Uniform fluorescence and no organ lesions were observed in germ-free mice, rats, and guinea pigs dosed with GCAs and in control animals (mice, rats, and guinea pigs) dosed with sucrose. The results indicate that intravascular growth of GCA microbubbles occurs in the cecal and colonic wall of mice, leading to occlusive ischemia and necrosis in these intestinal segments and secondary gas embolisation in the liver. Transmural gas supersaturation in the cecal wall may explain the intravascular bubble growth in mice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12729717     DOI: 10.1016/s0041-008x(03)00101-7

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  4 in total

Review 1.  Safety of ultrasound contrast agents.

Authors:  Jarl A Jakobsen; Raymond Oyen; Henrik S Thomsen; Sameh K Morcos
Journal:  Eur Radiol       Date:  2005-01-21       Impact factor: 5.315

2.  Grey scale enhancement of rabbit liver and kidney by intravenous injection of a new lipid-coated ultrasound contrast agent.

Authors:  Ping Liu; Yun-Hua Gao; Kai-Bin Tan; Zheng Liu; Song Zuo
Journal:  World J Gastroenterol       Date:  2004-08-15       Impact factor: 5.742

3.  Does contrast-enhanced cervical ultrasonography improve preoperative localization results in patients with sporadic primary hyperparathyroidism?

Authors:  Elias Karakas; Susanne Kann; Helmut Höffken; Detlef Klaus Bartsch; Ilhan Celik; Christian Görg; Andreas Pfestroff
Journal:  J Clin Imaging Sci       Date:  2012-10-31

4.  Therapeutic Dose Response of Acoustic Cluster Therapy in Combination With Irinotecan for the Treatment of Human Colon Cancer in Mice.

Authors:  Nigel Bush; Andrew Healey; Anant Shah; Gary Box; Vladimir Kirkin; Spiros Kotopoulis; Svein Kvåle; Per Christian Sontum; Jeffrey Bamber
Journal:  Front Pharmacol       Date:  2019-11-19       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.